Chief Financial Officer & Managing Director

Greg Weaver

Greg Weaver brings extensive experience in finance, having held numerous executive positions in the field of biotechnology. Greg’s career has focused on start-up through clinical development and commercial stage. He has guided over $1.1 billion in financing transactions during his career, participated in several public and private financings, providing financial guidance, strategic leadership and shareholder value. Prior to joining atai, Mr. Weaver was CFO at several successful companies, including SIRNA Therapeutics, ILEX Oncology, Oryzon, Prometic, and Eloxx Pharmaceuticals.

Mr. Weaver holds a BS in accounting and finance from Trinity University and an MBA from Boston College’s Wallace E. Carroll Graduate School of Management.

<<  Back to our team